Selected Grants
Pridopine EAP 2 (Clinical Site Agreement)
ResearchPrincipal Investigator · Awarded by Massachusetts General Hospital · 2024 - 2027An Intermediate Expanded Access Protocol (EAP) with CNM-Au8 for Amyotrophic Lateral Sclerosis
ResearchPrincipal Investigator · Awarded by Clene Nanomedicine Inc. · 2024 - 2026Pilot Trial to Investigate The Safety, Tolerability and Preliminary Efficacy of BL-001 Probiotic in People with ALS
Clinical TrialPrincipal Investigator · Awarded by Hop On A Cure · 2024 - 2026Bedlack - Pharmavite Donation Agreement A-027031 - ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform)
ResearchPrincipal Investigator · Awarded by Pharmavite LLC · 2023 - 2025ALSUntangled
ResearchPrincipal Investigator · Awarded by Amyotrophic Lateral Sclerosis Association · 2022 - 2025Healy ALS Platform Study - Regimen G - DNL343 TO#12
Clinical TrialPrincipal Investigator · Awarded by Massachusetts General Hospital · 2023 - 2025Duke ALS Clinic & Duke Telemedicine ALS Clinic
Institutional SupportPrincipal Investigator · Awarded by Amyotrophic Lateral Sclerosis Association · 2022 - 2025Intermediate Expanded Access Protocol CNMAu8.EAP02
Clinical TrialPrincipal Investigator · Awarded by Clene Nanomedicine Inc. · 2023 - 2025Healy ALS Platform study - Regimen F ABBV-CLS-7262 TO#11
Clinical TrialPrincipal Investigator · Awarded by Massachusetts General Hospital · 2023 - 2024Healy ALS Platform study - Regimen E ¿ Trehalose TO#10
Clinical TrialPrincipal Investigator · Awarded by Massachusetts General Hospital · 2021 - 2024A PHASE 2B/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12 MONTH CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MN-166 (IBUDILAST) FOLLOWED BY AN OPEN-LABEL EXTENSION IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS
Clinical TrialPrincipal Investigator · Awarded by MediciNova, INC. · 2020 - 2024Clinical Research in ALS & Related Disorders for Therapeutic Development (CReATE)
ResearchPrincipal Investigator · Awarded by University of Miami · 2019 - 2024Retrospective Analysis of Survival Outcomes Among Patients with Amyotrophic Lateral Sclerosis Who Received an Investigational Treatment, NP001, in Phase 2 Clinical Trials
ResearchPrincipal Investigator · Awarded by Neuvivo, Inc. · 2023 - 2024The Duke ALS Association Certified Center
Institutional SupportPrincipal Investigator · Awarded by Amyotrophic Lateral Sclerosis Association · 2018 - 2024Healey ALS Platform Trial Open Label Extension Zilucoplan
Clinical TrialPrincipal Investigator · Awarded by Massachusetts General Hospital · 2020 - 2023Potential Role of the Gut Microbiome in ALS Progression and Reversals
ResearchPrincipal Investigator · Awarded by Augie's Quest to Cure ALS · 2021 - 2023I AM ALS
Clinical TrialPrincipal Investigator · Awarded by Massachusetts General Hospital · 2021 - 2022Potential Role of the Gut Microbiome in ALS Progression
ResearchPrincipal Investigator · Awarded by Martha Olson-Fernandez Foundation · 2021 - 2022ALS Telemedicine
ResearchPrincipal Investigator · Awarded by Amyotrophic Lateral Sclerosis Association · 2021 - 2022EFFECTS OF ORAL LEVOSIMENDAN (ODM-109) ON RESPIRATORY FUNCTION IN PATIENTS WITH ALS: OPEN-LABEL EXTENSION FOR PATIENTS COMPLETING STUDY 3119002
Clinical TrialPrincipal Investigator · Awarded by Orion Corporation · 2019 - 2021ALS Telemedicine
ResearchPrincipal Investigator · Awarded by Amyotrophic Lateral Sclerosis Association · 2020 - 2021Identification of diagnostic peptides for the detection of sporadic amyotrophic lateral sclerosis (sALS)
ResearchPrincipal Investigator · Awarded by Affinergy, LLC · 2020 - 2020A Pilot Trial of Triheptanoin for People with Amyotrophic Lateral Sclerosis (PALS)
Clinical TrialPrincipal Investigator · Awarded by Ultragenyx Pharmaceutical · 2018 - 2020Duke ALS Telemedicine Clinic
ResearchPrincipal Investigator · Awarded by Amyotrophic Lateral Sclerosis Association · 2018 - 2020Integrated Genomics in Clinical ALS (GTAC)
ResearchPrincipal Investigator · Awarded by Columbia University · 2016 - 2019Protocol CY 5022: A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, DOSE-RANGING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CK-2127107 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Clinical TrialPrincipal Investigator · Awarded by Cytokinetics, Inc. · 2017 - 2019Clinical Research in ALS & Related Disorders for Therapeutic Development (CREATE)
ResearchPrincipal Investigator · Awarded by University of Miami · 2014 - 2019A Phase 2 Pharmacodynamic Study of Ezogabine on Neuronal Excitability in Amyotrophic Lateral Sclerosis
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline · 2015 - 2018A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects with Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation
Clinical TrialPrincipal Investigator · Awarded by Neuraltus Pharmaceuticals, Inc · 2016 - 2018A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY -ALS (CY 4031)
Clinical TrialPrincipal Investigator · Awarded by Cytokinetics, Inc. · 2016 - 2018A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerabiliity and Efficacy of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis ( ALS)
Clinical TrialPrincipal Investigator · Awarded by Cytokinetics, Inc. · 2015 - 2018HDE Post-Approval Study (PAS) of NeuRx DPS for ALS
Clinical TrialPrincipal Investigator · Awarded by Synapse Biomedical, Inc · 2013 - 2018External Relationships
- AB Science
- ALS Association
- American Institute of Biological Sciences
- Amylyx
- Annexon Biosciences, Inc.
- Betty's Brigade
- Biogen Idec Inc.
- Carespace Health Inc.
- Clene Nanomedicine
- Eikonoklastes
- Eisenhower Medical Center
- General Dynamics Information Technology
- Genieus
- Guidepoint Global
- IONIS Pharmaceuticals
- Kaplan
- MJH Life Sciences
- Neurosense
- Novartis pharmaceuticals
- PTC Therapeutics
- Prime Education
- Roon
- Springer Publishing Company
- State of Maryland
- The CM Group
- Uniqure
- WebMD/Medscape
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.